Adult: Schizophrenia: Other psychoses, especially paranoid (oral & IM), Mania & hypomania (oral & IM), Mental or behavioral problems such as aggression, hyperactivity & self- mutilations in the mentally retarded & in patients with organic brain damage, severe psychomotor agitation, excitement, violent or dangerously impulsive behavior (oral & IM), Intractable hiccup (oral), Restlessness & agitation in the elderly (oral), Gilles de la Tourette syndrome & severe tics (oral), Nausea & vomiting (IM), Children (Oral administration only) : Childhood behavioral disorders especially when associated with hyperactivity & aggression, Gilles de la Tourette syndrome, Childhood schizophrenia.
Butyrophenone; Antipsychotic
Haloperidol is a butyropherone derivative with antipsychotic properties that has been considered particularly effective in the management of hyperactivity, agitation and mania. Haloperidol is an effective neuroleptic and also possesses antiemetic properties. It may also exhibit hypothermic and anorexiant effects and potentiate the action of barbiturates, general anesthetics and other CNS depressant drugs. Haloperidol is a quick acting substance and has a duration of action of about 12 hours after one single administration. The optimum daily therapy consists of 2 administrations.
Initial dosage: Moderate symptomatology 1.5- 3.0 mg bd or tds.
Haloperidol has been reported to interfere with the anticoagulant properties of phenindione in an isolated case and the possibility should be kept in mind of a similar effect occurring when haloperidol is used with other anticoagulants. Haloperidol may antagonize the action of epinephrine and other sympathomimetic agents and reverse the blood pressure-lowering effects of adrenergic-blocking agents, such as guanethidine. Enhanced CNS effects may occur when haloperidol is used in combination with methyldopa. Haloperidol inhibits the metabolization of tricyclic antidepressants, thereby increasing plasma levels of these drugs. This may result in increased tricyclic antidepressant toxicity (anticholinergic effects, cardiovascular toxicity, lowering of seizure threshold). Haloperidol may impair the antiparkinson effects of levodopa. If an antiparkinson agent is used concomitantly with haloperidol, both drugs should not be discontinued simultaneously, since extrapyramidal symptoms may occur due to the slower excretion rate of haloperidol.
CNS depression; Parkinson’s disease; known hypersensitivity to haloperidol; lesions of the basal ganglia.
Extrapyramidal symptoms, acute dystonia, parkinsonian rigidity, tremor, oculogyric crises & laryngeal dystonia, confusional states or epileptic fits, depression, sedation, agitation, drowsiness, insomnia, headache, vertigo & apparent exacerbation of psychotic symptoms, nausea, loss of appetite, constipation & dyspepsia, dry mouth, blurred vision, urinary retention.
There is no proven harmful Effect in the first trimester.
In general, the symptoms of overdosage would be an exaggeration of known pharmacologic effects and adverse reactions, the most prominent of which would be: severe extrapyramidal reactions, hypotension or sedation.The patient would appear comatose with respiratory depression and hypotension which could be severe enough to produce a shock-like state.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)